These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

166 related articles for article (PubMed ID: 32424876)

  • 1. PD-L1 expression on tumor or stromal cells of nodal cytotoxic T-cell lymphoma: A clinicopathological study of 50 cases.
    Yamashita D; Shimada K; Kohno K; Kogure Y; Kataoka K; Takahara T; Suzuki Y; Satou A; Sakakibara A; Nakamura S; Asano N; Kato S
    Pathol Int; 2020 Aug; 70(8):513-522. PubMed ID: 32424876
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Clinicopathological features of programmed cell death-1 and programmed cell death-ligand-1 expression in the tumor cells and tumor microenvironment of angioimmunoblastic T cell lymphoma and peripheral T cell lymphoma not otherwise specified.
    Kim S; Kwon D; Koh J; Nam SJ; Kim YA; Kim TM; Kim CW; Jeon YK
    Virchows Arch; 2020 Jul; 477(1):131-142. PubMed ID: 32170448
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Immunohistochemical assessment of the diagnostic utility of PD-L1: a preliminary analysis of anti-PD-L1 antibody (SP142) for lymphoproliferative diseases with tumour and non-malignant Hodgkin-Reed-Sternberg (HRS)-like cells.
    Sakakibara A; Kohno K; Eladl AE; Klaisuwan T; Ishikawa E; Suzuki Y; Shimada S; Nakaguro M; Shimoyama Y; Takahara T; Kato S; Asano N; Nakamura S; Satou A
    Histopathology; 2018 Jun; 72(7):1156-1163. PubMed ID: 29380399
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Clinicopathological analysis of primary intestinal diffuse large B-cell lymphoma: Prognostic evaluation of CD5, PD-L1, and Epstein-Barr virus on tumor cells.
    Ishikawa E; Kato S; Shimada K; Tanaka T; Suzuki Y; Satou A; Kohno K; Sakakibara A; Yamamura T; Nakamura M; Miyahara R; Goto H; Nakamura S; Hirooka Y
    Cancer Med; 2018 Dec; 7(12):6051-6063. PubMed ID: 30449068
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Clinicopathological evaluation of the programmed cell death 1 (PD1)/programmed cell death-ligand 1 (PD-L1) axis in post-transplant lymphoproliferative disorders: association with Epstein-Barr virus, PD-L1 copy number alterations, and outcome.
    Veloza L; Teixido C; Castrejon N; Climent F; Carrió A; Marginet M; Soldini D; González-Farré B; Ribera-Cortada I; Lopez-Guillermo A; González-Barca E; Sierra A; Herrera M; Gómez C; Garcia A; Balagué O; Campo E; Martinez A
    Histopathology; 2019 Dec; 75(6):799-812. PubMed ID: 30861172
    [TBL] [Abstract][Full Text] [Related]  

  • 6. PD-L1 expression on neoplastic or stromal cells is respectively a poor or good prognostic factor for adult T-cell leukemia/lymphoma.
    Miyoshi H; Kiyasu J; Kato T; Yoshida N; Shimono J; Yokoyama S; Taniguchi H; Sasaki Y; Kurita D; Kawamoto K; Kato K; Imaizumi Y; Seto M; Ohshima K
    Blood; 2016 Sep; 128(10):1374-81. PubMed ID: 27418641
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Large cell morphology, CMYC+ tumour cells, and PD-1+ tumour cell/intense PD-L1+ cell reactions are important prognostic factors in nodal peripheral T-cell lymphomas with T follicular helper markers.
    Mihashi Y; Kimura S; Iwasaki H; Oshiro Y; Takamatsu Y; Kawauchi S; Shimajiri S; Ishizuka K; Takeshita M
    Diagn Pathol; 2021 Nov; 16(1):101. PubMed ID: 34742294
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Nodal EBV+ cytotoxic T-cell lymphoma: A literature review based on the 2017 WHO classification.
    Kato S; Yamashita D; Nakamura S
    J Clin Exp Hematop; 2020; 60(2):30-36. PubMed ID: 32565530
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Enhanced PD-L1 expression on tumor cells in primary CD30-positive cutaneous large T-cell lymphoma: a report of lymph node lesions of four cases.
    Takahashi E; Imai H; Tsuyuki Y; Taniguchi N; Kogure Y; Kataoka K; Tsuchida T; Baba S; Tsuzuki T; Shimauchi T; Nakamura S
    J Clin Exp Hematop; 2023; 63(1):49-57. PubMed ID: 36990776
    [TBL] [Abstract][Full Text] [Related]  

  • 10. T-cell receptor (TCR) phenotype of nodal Epstein-Barr virus (EBV)-positive cytotoxic T-cell lymphoma (CTL): a clinicopathologic study of 39 cases.
    Kato S; Asano N; Miyata-Takata T; Takata K; Elsayed AA; Satou A; Takahashi E; Kinoshita T; Nakamura S
    Am J Surg Pathol; 2015 Apr; 39(4):462-71. PubMed ID: 25634749
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Epstein-Barr virus-positive nodal T/NK-cell lymphoma: an analysis of 15 cases with distinct clinicopathological features.
    Jeon YK; Kim JH; Sung JY; Han JH; Ko YH;
    Hum Pathol; 2015 Jul; 46(7):981-90. PubMed ID: 25907865
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Nodal cytotoxic molecule (CM)-positive Epstein-Barr virus (EBV)-associated peripheral T cell lymphoma (PTCL): a clinicopathological study of 26 cases.
    Kato S; Takahashi E; Asano N; Tanaka T; Megahed N; Kinoshita T; Nakamura S
    Histopathology; 2012 Aug; 61(2):186-99. PubMed ID: 22690710
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Clinicopathological analysis of neoplastic PD-L1-positive EBV
    Takahara T; Satou A; Ishikawa E; Kohno K; Kato S; Suzuki Y; Takahashi E; Ohashi A; Asano N; Tsuzuki T; Nakamura S
    Virchows Arch; 2021 Mar; 478(3):541-552. PubMed ID: 32803453
    [TBL] [Abstract][Full Text] [Related]  

  • 14. FoxP3-positive T cell lymphoma arising in non-HTLV1 carrier: clinicopathological analysis of 11 cases of PTCL-NOS and 2 cases of mycosis fungoides.
    Satou A; Asano N; Kato S; Katsuya H; Ishitsuka K; Elsayed AA; Nakamura S
    Histopathology; 2016 Jun; 68(7):1099-108. PubMed ID: 26426838
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Enhanced PD-L1 expression on tumor cells in primary cutaneous large T-cell lymphoma with CD30 expression as classic Hodgkin lymphoma mimics: A report of lymph node lesions of two cases.
    Takahashi E; Tsuchida T; Baba S; Tsuzuki T; Shimauchi T; Tokura Y; Tamada Y; Nakamura S
    Pathol Int; 2020 Oct; 70(10):804-811. PubMed ID: 32783303
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The perivascular microenvironment in Epstein-Barr virus positive primary central nervous system lymphoma: The role of programmed cell death 1 and programmed cell death ligand 1.
    Sugita Y; Furuta T; Ohshima K; Komaki S; Miyoshi J; Morioka M; Abe H; Nozawa T; Fujii Y; Takahashi H; Kakita A
    Neuropathology; 2018 Apr; 38(2):125-134. PubMed ID: 29067721
    [TBL] [Abstract][Full Text] [Related]  

  • 17. PD1/PD-L1 Expressions in Plasmablastic Lymphoma with Clinicopathological Correlation.
    Rosado FG; Coberly J; Gupta A; John G; Naina H; Koduru P; Chen W
    Ann Clin Lab Sci; 2021 Mar; 51(2):174-181. PubMed ID: 33941556
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Expression of Immune Checkpoint Regulators, Cytotoxic T-Lymphocyte Antigen-4, and Programmed Death-Ligand 1 in Epstein-Barr Virus-associated Nasopharyngeal Carcinoma.
    Ahmed MM; Gebriel MG; Morad EA; Saber IM; Elwan A; Salah M; Fakhr AE; Shalaby AM; Alabiad MA
    Appl Immunohistochem Mol Morphol; 2021 Jul; 29(6):401-408. PubMed ID: 33480605
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Reappraisal of nodal Epstein-Barr Virus-negative cytotoxic T-cell lymphoma: Identification of indolent CD5
    Yamashita D; Shimada K; Takata K; Miyata-Takata T; Kohno K; Satou A; Sakakibara A; Nakamura S; Asano N; Kato S
    Cancer Sci; 2018 Aug; 109(8):2599-2610. PubMed ID: 29845715
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Expression of programmed death ligand 1 is associated with poor prognosis in myeloid sarcoma patients.
    Kawamoto K; Miyoshi H; Suzuki T; Kiyasu J; Yokoyama S; Sasaki Y; Sone H; Seto M; Takizawa J; Ohshima K
    Hematol Oncol; 2018 Aug; 36(3):591-599. PubMed ID: 29602174
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.